{"protocolSection":{"identificationModule":{"nctId":"NCT04285060","orgStudyIdInfo":{"id":"00210372"},"organization":{"fullName":"Samsung Electronics","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy of Samsung GEMS-H Device Training in Sub-Acute and Chronic Stroke","officialTitle":"Safety and Efficacy on Functional Mobility Following Samsung GEMS-H Device Training in Sub-Acute and Chronic Stroke: A Pivotal Study"},"statusModule":{"statusVerifiedDate":"2021-09","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-02-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2021-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-02-24","studyFirstSubmitQcDate":"2020-02-24","studyFirstPostDateStruct":{"date":"2020-02-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-09-24","lastUpdatePostDateStruct":{"date":"2021-09-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Samsung Electronics","class":"INDUSTRY"},"collaborators":[{"name":"Shirley Ryan AbilityLab","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUnapprovedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"A single-site, interventional, single-arm trial to evaluate the safety and efficacy on functional mobility following Samsung GEMS-H (Gait Enhancing and Motivating System - Hip) device training in participants with sub-acute and chronic stroke."},"conditionsModule":{"conditions":["Stroke","Chronic Stroke"],"keywords":["Stroke","Exoskeleton"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"OTHER","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Training Group","type":"EXPERIMENTAL","description":"All participants are assigned to the training group with the Samsung GEMS-H.","interventionNames":["Device: Samsung GEMS-H"]}],"interventions":[{"type":"DEVICE","name":"Samsung GEMS-H","description":"Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.","armGroupLabels":["Training Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of device related adverse events","description":"Safety will be assessed by the number of device related adverse events throughout the duration of the study","timeFrame":"Duration of study participation (estimated 6 months)"},{"measure":"10 Meter Walk Test (Self-selected walking speed) (10MWT-SS)","description":"Change in self-selected walking speed measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks)"}],"secondaryOutcomes":[{"measure":"6 Minute Walk Test (6MWT)","description":"Change in walking endurance measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks)"},{"measure":"Berg Balance Scale (BBS)","description":"Changes in functional balance measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks)"},{"measure":"Functional Gait Assessment (FGA)","description":"Change in functional balance measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks)"}],"otherOutcomes":[{"measure":"Incidence of device malfunctions","description":"Device reliability will be assessed by the number of device malfunctions throughout the duration of the study","timeFrame":"Duration of study (estimated 12 months)"},{"measure":"ActiGraph activity monitor","description":"Changes in average daily step count","timeFrame":"Duration of study participation (estimated 4 months)"},{"measure":"Transcranial Magnetic Stimulation (TMS)","description":"Measure changes in descending corticospinal drive to the lower limb muscles","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks)"},{"measure":"10 Meter Walk Test (Self-selected walking speed) (10MWT-SS)","description":"Changes in self-selected walking speed measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"10 Meter Walk Test (Fastest walking speed) (10MWT-FS)","description":"Changes in fastest walking speed measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"10 Meter Walk Test (Self-selected walking speed) (10MWT-SS) with the device","description":"Changes in self-selected walking speeds between two conditions (with and without the device)","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"10 Meter Walk Test (Fastest walking speed) (10MWT-FS) with the device","description":"Changes in fastest walking speeds between two conditions (with and without the device)","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"6 Minute Walk Test (6MWT)","description":"Changes in walking endurance measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"6 Minute Walk Test (6MWT) with the device","description":"Changes in walking endurance between two conditions (with and without the device)","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Berg Balance Scale (BBS)","description":"Changes in functional balance measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Functional Gait Assessment (FGA)","description":"Change in functional balance measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"5 Times Sit to Stand Test (5xSST)","description":"Change in lower extremity strength measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Gait analysis using a gait mat","description":"Changes in spatiotemporal parameters measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA)","description":"Changes in motor recovery measured without the device","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Manual Muscle Testing (MMT)","description":"Changes in leg strength measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Modified Ashworth Test (MAS)","description":"Changes in leg spasticity measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Passive Range of Motion (PROM)","description":"Changes in passive range of motion in leg joints measured without the device","timeFrame":"Baseline, Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Modified Falls Efficacy Scale (mFES)","description":"Changes in perception of balance and stability","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Activities-specific and Balance Confidence Scale (ABC)","description":"Changes in confidence in performing various ambulatory activities without falling","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Stoke Impact Scale (SIS)","description":"Changes in the measure of the impact of stroke on overall physical and cognitive function","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Patient Health Questionnaire-9 (PHQ-9)","description":"Changes in depression","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Stroke Specific Quality of Life (SSQoL)","description":"Changes in the health-related quality of life","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"},{"measure":"Oxygen Consumption using Cosmed K4b2","description":"Changes in metabolic energy expenditure","timeFrame":"Baseline, Mid-Intervention (estimated 4 weeks), Post-Intervention (estimated 8 weeks), 1 month Post-Intervention (1 month follow-up)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 30-days post stroke\n* Age: 18-85 Years\n* Initial gait speed of ≥ 0.4 m/s and ≤ 0.8 m/s\n* Adequate cognitive function (MMSE score \\>17)\n* Ability to walk at least 10m with maximum 1 person assist\n* Physician approval for patient participation\n* Able to safely fit into device specifications and tolerate minimum assistance\n\nExclusion Criteria:\n\n* ≤90 days post major orthopedic surgery (i.e. hip, knee, and/or ankle joint replacement)\n* ≤ 6 months post coronary artery bypass graft (CABG) or cardiac valve procedure\n* Severe osteoporosis as indicated by physician medical clearance\n* Serious cardiac conditions (hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living)\n* Pregnancy\n* Uncontrolled hypertension\n* Lower extremity fracture\n* Modified Ashworth Spasticity ≥3 in hip flexor or extensor\n* Preexisting neurological disorders such as Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), dementia\n* History of: major head trauma, lower extremity amputation, non-healing ulcers of a lower extremity, ongoing active infections, legal blindness, or a history of significant psychiatric illness\n* Participating in any other structured outpatient, home health physical therapy program, or another clinical trial that according to the Principal Investigator is likely to affect study outcome or confound results.\n\nTMS-Specific Exclusion Criteria\n\n* Pacemakers, metal implants in the head region\n* History of unexplained, recurring headaches, epilepsy/seizures/skull fractures or skull deficits\n* Medications that lower seizure threshold\n* History of concussion in last 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Arun Jayaraman, Ph.D.","role":"CONTACT","phone":"+1-312-238-6875","email":"ajayaraman@sralab.org"},{"name":"Kristen Hohl, DPT","role":"CONTACT","phone":"+1-312-238-2640","email":"khohl@sralab.org"}],"locations":[{"facility":"Shirley Ryan AbilityLab","status":"RECRUITING","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","contacts":[{"name":"Arun Jayaraman, Ph.D.","role":"CONTACT","email":"ajayaraman@sralab.org"}],"geoPoint":{"lat":41.85003,"lon":-87.65005}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}